高昂费用及频发的不良反应：转移性肾细胞癌一线治疗用药卡博替尼的未来之路

doi:10.3969/j.issn.1009-976X.2021.04.003

岭南现代临床外科 ›› 2021, Vol. 21 ›› Issue (04): 387-391.DOI: 10.3969/j.issn.1009-976X.2021.04.003

高昂费用及频发的不良反应：转移性肾细胞癌一线治疗用药卡博替尼的未来之路

杨晶莹^1,2,3, 谢英伟^1,2,3, 朱定军^1,3, 谢文练^1,2,3,*

1.中山大学孙逸仙纪念医院泌尿外科,广州 510289;
2.中山大学孙中山纪念医院广东省恶性肿瘤表观遗传学与基因调控重点实验室,广州 510289;
3.广东省泌尿外科疾病临床研究中心,广州 510289

通讯作者: *谢文练,主任医师,博士研究生导师,Email: xiewl@mail.sysu.edu.cn
作者简介:谢文练,教授，主任医师,博士生导师,中山大学孙逸仙纪念医院泌尿外科教授，从事泌尿外科的医教研工作30 余年。在泌尿系结石、肿瘤、前列腺增生及肾上腺肿瘤、尿道狭窄、男性泌尿生殖系畸形等疾病的诊断和治疗方面积累了丰富的临床经验，擅长腔内泌尿外科窥镜手术、腹腔镜手术、复杂性尿路结石手术开放性手术等。获得并主持多项国家自然科学基金及广东省自然科学基金。
基金资助:
广东省自然科学基金（2019A1515012199）; 广东省泌尿外科疾病临床研究中心（2020B1111170006）

High cost and frequent adverse events： the future of Cabozantinib for the first-line treatment of metastatic renal cell carcinoma

YANG Jing-ying^1,2,3, XIE Ying-wei^1,2,3, ZHU Ding-jun^1,3, XIE Wen-lian^1,2,3

1. Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University;
2. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University;
3. Guangdong Provincial Clinical Research Center for Urological Diseases, Guangzhou 510289, China

Online:2021-08-20 Published:2021-12-09
Contact: XIE Wen-lian, xiewl@mail.sysu.edu.cn

摘要/Abstract

摘要： 转移性肾细胞癌的药物治疗是目前讨论的热点,2020版EAU肾癌诊治指南首次承认了卡博替尼的作用,并将其列为不能接受免疫检查点抑制治疗患者的一线用药。本文将从卡博替尼的作用机制、治疗方案、治疗效果、不良反应及治疗的费用成本方面进行阐述,详细分析卡博替尼的优劣势,并将其与舒尼替尼进行比较,进一步探讨卡博替尼治疗转移性肾癌的前景。

关键词: 转移性肾癌, 卡博替尼, 舒尼替尼

Abstract: The drug treatment of metastatic renal cell carcinoma is the focus at present. The 2020 edition of EAU guidelines of renal cell carcinoma recognizes the role of Cabozantinib for the first time and lists it as the first-line treatment for patients who cannot accept immune checkpoint inhibition treatment. This paper will elaborate the treatment mechanism, treatment scheme, treatment effect, adverse events and treatment cost of Cabozantinib, and analyze the advantages and disadvantages of Cabozantinib in detail. It will also compare Cabozantinib with sunitinib, and further explore the prospect of Cabozantinib for metastatic renal cell carcinoma.

Key words: metastatic renal cell carcinoma, Cabozantinib, sunitinib

中图分类号:

R737.11

杨晶莹, 谢英伟, 朱定军, 谢文练. 高昂费用及频发的不良反应：转移性肾细胞癌一线治疗用药卡博替尼的未来之路[J]. 岭南现代临床外科, 2021, 21(04): 387-391.

YANG Jing-ying, XIE Ying-wei, ZHU Ding-jun, XIE Wen-lian. High cost and frequent adverse events： the future of Cabozantinib for the first-line treatment of metastatic renal cell carcinoma[J]. Lingnan Modern Clinics In Surgery, 2021, 21(04): 387-391.

参考文献

[1] 朱刚, 刘圣杰. 2020版欧洲泌尿外科学会(EAU)肾癌诊疗指南更新解读[J]. 中华腔镜泌尿外科杂志(电子版),2021,15(1):1-3.
[2] Stukalin I, Wells JC, Graham J, et al.Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium[J]. Curr Oncol,2019,26(2):e175-e179.
[3] Santoni M, Heng DY, Bracarda S, et al.Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors[J]. Cancers (Basel),2019,12(1): 84.
[4] Lemmon MA, Schlessinger J.Cell signaling by receptor tyrosine kinases[J]. Cell,2010,141(7):1117-1134.
[5] Koch S, Claesson-Welsh L.Signal transduction by vascular endothelial growth factor receptors[J]. Cold Spring Harb Perspect Med,2012,2(7):a006502.
[6] Gossage L, Eisen T, Maher ER.VHL, the story of a tumour suppressor gene[J]. Nat Rev Cancer,2015,15(1):55-64.
[7] Paez-Ribes M, Allen E, Hudock J, et al.Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis[J]. Cancer Cell,2009,15(3):220-231.
[8] Corso S, Giordano S.Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective[J]. Cancer Discov,2013,3(9):978-992.
[9] 陈娜, 詹世鹏, 刘芳. 卡博替尼治疗肾细胞癌的疗效与安全性评价及其管理措施[J]. 中国新药杂志,2020,29(11):1265-1269.
[10] Shojaei F, Lee JH, Simmons BH, et al.HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors[J].Cancer Res,2010,70(24):10090-10100.
[11] Li Y, Ye X, Tan C, et al.Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis[J]. Oncogene,2009,28(39):3442-3455.
[12] Abdelaziz A, Vaishampayan U.Cabozantinib for the treatment of kidney cancer[J]. Expert Rev Anticancer Ther,2017,17(7):577-584.
[13] George DJ, Hessel C, Halabi S, et al.Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial[J]. Oncologist,2019,24(11):1497-1501.
[14] Pal SK, Tangen C, Thompson IM, Jr, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial[J]. Lancet,2021,397(10275):695-703.
[15] Albiges L, Flechon A, Chevreau C, et al.Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program[J]. Eur J Cancer,2021,142:102-111.
[16] Schmidinger M, Danesi R.Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma[J]. Oncologist,2018,23(3):306-315.
[17] Choueiri TK, Hessel C, Halabi S, et al.Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update[J]. Eur J Cancer,2018,94:115-125.
[18] Chen RC, Choueiri TK, Feuilly M, et al.Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)[J]. Cancer,2020,126(24):5311-5318.
[19] Choueiri TK, Escudier B, Powles T, et al.Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial[J]. Lancet Oncol,2016,17(7):917-927.
[20] Lacy S, Nielsen J, Yang B, et al.Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma[J]. Cancer Chemother Pharmacol,2018,81(6):1061-1070.
[21] Giuliani J, Bonetti A.Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma[J]. Clin Genitourin Cancer,2019,17(2):e258-e262.
[22] Swallow E, Messali A, Ghate S, et al.The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma[J]. J Manag Care Spec Pharm,2018,24(4):335-343.
[23] Meng J, Lister J, Vataire AL, et al.Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England[J]. Clinicoecon Outcomes Res,2018,10:243-250.
[24] Kim S, Han S, Kim H, Suh HS.Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea[J]. Appl Health Econ Health Policy, 2021,19(4): 545-555.

高昂费用及频发的不良反应：转移性肾细胞癌一线治疗用药卡博替尼的未来之路

High cost and frequent adverse events： the future of Cabozantinib for the first-line treatment of metastatic renal cell carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

编辑推荐

Metrics

[1]	钟启宇, 谢文练. circZBTB44通过调控AKT通路促进肾透明细胞癌增殖和迁移的研究[J]. 岭南现代临床外科, 2021, 21(03): 302-308.
[2]	胡师华, 韦康来. 锌指蛋白521在肾母细胞瘤的表达及转录调控预测研究[J]. 岭南现代临床外科, 2020, 20(06): 774-783.
[3]	陈志良, 谢文练. circDOCK4促进肾透明细胞癌细胞增殖、迁移和侵袭的研究[J]. 岭南现代临床外科, 2020, 20(02): 139-145.
[4]	向柯旭，李少华，唐菊英，张小云，张少玲，郭颖*. 醛固酮瘤中长链非编码RNA的差异表达及功能分析[J]. 岭南现代临床外科, 2019, 19(01): 38-43.
[5]	陈海城，蔡宇弘，郑灶松，陈志良，谢文练*. LINC00475 在肾癌中的临床意义及其对肾癌细胞 786?O 的影响[J]. 岭南现代临床外科, 2018, 18(02): 162-166.
[6]	郑灶松陈海城谢文练. 长链非编码 RNA MIAT 在肾透明细胞癌中的表达情况和预后意义[J]. 岭南现代临床外科, 2017, 17(04): 391-394.
[7]	金小岩张萌王吉文. 妊娠合并嗜铬细胞瘤的诊断与治疗(附3例报告)[J]. 岭南现代临床外科, 2015, 15(05): 614-616.
[8]	李华强袁坚唐云峰陈少娜. 肾癌根治术患者手术前后CD8+CD28-T细胞表达及临床意义[J]. 岭南现代临床外科, 2015, 15(02): 219-221.
[9]	陈怡叶秋萍刘鑫宫君原李淑琴. 表达肾癌G250基因和hGM-CSF基因HEK293细胞系的建立[J]. 岭南现代临床外科, 2011, 11(04): 270-273.